What Has Been the Progress and Growth of the Cardiometabolic Diseases Market in Recent Years?
The cardiometabolic diseases market has seen considerable growth due to a variety of factors.
•Over the past few years, the cardiometabolic diseases market has seen a constant increase in size. The market size is projected to increase from $111.64 billion in 2024 to $115.7 billion in 2025, marking a compound annual growth rate (CAGR) of 3.6%.
This growth over time can be attributed to factors such as sedentary lifestyles, changes in lifestyle due to urbanisation, an increase in processed food intake due to industrialisation, genetic vulnerability, and environmental aspects.
What Can Be Expected from the Cardiometabolic Diseases Market in the Coming Years?
The cardiometabolic diseases market is expected to maintain its strong growth trajectory in upcoming years.
• The market for cardiometabolic diseases is anticipated to witness consistent expansion in the coming years. The market is projected to reach $137.81 billion by 2029, with a compound annual growth rate (CAGR) of 4.5%.
The projected growth over the forecast period can be ascribed to factors such as the prevalence of obesity, continued aging population, enhancements in healthcare infrastructure, advancements in genomic and precision medicine, as well as chronic stress and mental health. Key trends during the forecast period incorporate health education and awareness, corporate wellness schemes, local health initiatives, healthcare with a focus on prevention and integrated care strategies.
What Are The Leading Drivers Of Growth In The Cardiometabolic Diseases Market?
The advancement of the cardiometabolic disease market is predicted to be spurred by a high obesity incidence rate. Obesity, a multifaceted health issue caused by high body fat accumulation that results in an increased overall body weight, is intrinsically linked to the rise of cardiovascular risk contributors such as dyslipidemia, type 2 diabetes, hypertension, and sleep disturbances. For example, the World Health Organization (WHO), an intergovernmental organization based in Switzerland, reported in March 2022 that over 1 billion people across the globe were impacted by obesity, with a breakdown including 340 million adolescents, 650 million adults, and 39 million children on an annual basis. By 2025, the WHO anticipates that 167 million individuals, both adults and children, will suffer health deterioration due to being overweight or obese. Consequently, the escalating obesity prevalence continues to push the expansion of the cardiometabolic disease market.
How Are The Segments Defined Within The Global Cardiometabolic Diseases Market?
The cardiometabolic diseases market covered in this report is segmented –
1) By Type: Chronic Or Congestive Heart Failure, Hypertension, Type 2 Diabetes, Obesity
2) By Treatment: ACE inhibitors, Diuretics, Glucophage, Liposuction, Other Treatments
3) By Dosage: Tablet, Injection
4) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration
5) By End-Users: Clinic, Hospital, Other End-Users
Subsegments:
1) By Chronic Or Congestive Heart Failure: Systolic Heart Failure, Diastolic Heart Failure
2) By Hypertension: Primary Hypertension, Secondary Hypertension
3) By Type 2 Diabetes: Insulin Resistance, Impaired Glucose Tolerance
4) By Obesity: Class I Obesity (BMI 30-34.9), Class II Obesity (BMI 35-39.9), Class III Obesity (BMI 40 And above)
Pre-Book The Cardiometabolic Diseases Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Cardiometabolic Diseases Market?
Embracing cutting-edge technologies is a leading trend emerging in the cardiometabolic diseases market. Businesses participating in the cardiometabolic diseases market are engaging innovative technologies to maintain their market dominance. For example, Eko Health Inc., an American company specializing in devising digital health technologies for heart and lung disease detection, introduced the Sensora cardiac disease detection platform in February 2023. This platform incorporates artificial intelligence that can accurately identify structural murmurs, indicating valvular heart disease (VHD), as well as a care pathway analytics system that provides valuable data and insights on a patient's journey through the healthcare system. A digital stethoscope on this platform is employed to record and scrutinize electrical impulses and heart rhythms.
Who Are the Key Players in the Cardiometabolic Diseases Market?
Major companies operating in the cardiometabolic diseases market include:
• Pfizer Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche AG
• Merck & Co Inc.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi SA
• Kowa Company Ltd.
• Thermo Fisher Scientific
• Abbott Laboratories
• Takeda Pharmaceutical Company
• Eli Lilly and Company
• Novo Nordisk A/S
• Siemens Healthineers
• Boehringer Ingelheim International GmbH
• Becton
• Dickinson and Company
• Stryker Corporation
• AstraZeneca Plc
• Viatris Inc.
• Biocrates Life Sciences AG
• Boston Scientific
• Astellas Pharma Inc.
• Terumo Corporation
• Agilent Technologies
• Edwards Lifesciences
• Bruker Corporation
• Alnylam Pharmaceuticals Inc.
• Arrowhead Pharmaceuticals Inc.
• Cardax Inc.
What Is The Most Dominant Region In The Cardiometabolic Diseases Market?
North America was the largest region in the cardiometabolic diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiometabolic diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
